Log in

NASDAQ:INHX - Inhibitex Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Inhibitex, Inc develops antibody-based products for the treatment and prevention of bacterial and fungal infections. The Company produces products that can be used as vaccines, binding inhibitors or separation supports for affinity purifications. The Company's lead product candidate, Veronate, which entered into Phase III clinical trial in the second half of 2004, is being developed for the prevention of hospital-associated infections in premature, very low birth weight, (VLBW) infants.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:INHX
CUSIPN/A
Phone+1-678-7461100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive INHX News and Ratings via Email

Sign-up to receive the latest news and ratings for INHX and its competitors with MarketBeat's FREE daily newsletter.


Inhibitex (NASDAQ:INHX) Frequently Asked Questions

What is Inhibitex's stock symbol?

Inhibitex trades on the NASDAQ under the ticker symbol "INHX."

Has Inhibitex been receiving favorable news coverage?

Headlines about INHX stock have been trending extremely negative on Sunday, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Inhibitex earned a news sentiment score of -4.5 on InfoTrie's scale. They also gave news coverage about the healthcare company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Inhibitex.

What is Inhibitex's official website?

The official website for Inhibitex is http://www.inhibitex.com/.

How can I contact Inhibitex?

Inhibitex's mailing address is 9005 Westside Pkwy, ALPHARETTA, GA 30009-4783, United States. The healthcare company can be reached via phone at +1-678-7461100.


MarketBeat Community Rating for Inhibitex (NASDAQ INHX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  220
MarketBeat's community ratings are surveys of what our community members think about Inhibitex and other stocks. Vote "Outperform" if you believe INHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel